Seeking information about the ABBOTT ID NOW test platform used to diagnose COVID-19.
Apparently Abbott purchased the analyzer business from Alere Inc, in 2018 that had developed the analyzer to provide point-of-contact in vitro diagnostics (IVD) of influenza A & B.
Published evaluations of the effectiveness of the Alere product analysis placed the sensitivity in the low 90% range with influenza A&B, and lower yet for specificity (distinguishing between A & B)
Now that the test analyzer is being utilized for COVID-19 diagnosis, I had some questions:
What is the cost of the analyzer, how many analyzers (repurposed for COVID-19 detection) are already in the field and finally what is the S&S for this analyzer when coupled with the COVID-19 specimen acquisition/test reagent kit?